ALLMedicine™ Essential Thrombocytosis Center
Research & Reviews 72 results
https://doi.org/10.1038/s41375-021-01254-w 10.1001/jama.1950.02910290018005 10.1182/blood-2001-12-0349 10.1182/blood-2016-03-643544 10.3324/haematol.2018.213108 10.1182/blood-2013-11-539098 10.1016/j.stem.2007.10.020 10.1038/nature12495 10.1016/j.cell.2013.08.007 10.1182/blood-2006-03-008805 10.1038/leu.2017.169 10.1182/bloodadvances.2019001407 10.1016/S0301-472X(01)00789-5 10.1038/ng.334 10.1200/JCO.2007.12.6896 10.3324/haematol.2014.107631 10.1002/ajh.25014 10.1016/j.exphem.2008.05.006 10.1371/journal.pone.0232801 10.3324/haematol.2018.215582 10.1056/NEJMoa1403141 10.1038/leu.2008.357 10.1634/stemcells.2006-0351 10.1182/blood-2011-06-364182
Leukemia Spivak JL
Apr 30th, 2021 - Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?|2021|Spivak JL,|
PloS One; Baik R, Wyman SK et. al.
Mar 5th, 2021 - Myeloproliferative neoplasms (MPNs) cause the over-production of blood cells such as erythrocytes (polycythemia vera) or platelets (essential thrombocytosis). JAK2 V617F is the most prevalent somatic mutation in many MPNs, but previous modeling of...
Cardiology Buber J, Guetta V et. al.
Feb 15th, 2021 - Percutaneous device closure was shown to effectively prevent recurrent strokes in patients with patent foramen ovale (PFO). Whether this protective effect is relevant for patients with hypercoagulable states (HCSs) is unknown as they were not repr...
Hematology. American Society of Hematology. Education Pro... Moliterno AR, Kaizer H
Dec 5th, 2020 - Polycythemia vera, essential thrombocytosis (ET), and primary myelofibrosis (PMF) are grouped together as myeloproliferative neoplasms (MPNs) because of shared clinical, pathologic, and molecular features. The 2005 discovery of the driver mutation...
Medicine Fricke J, Mambetsariev I et. al.
Nov 13th, 2020 - Patients reporting high PD-L1 expression have shown to respond well to immunotherapy; however, some patients develop hyperprogressive disease upon initiation of immune checkpoint inhibitors. We report a patient with lung cancer and 100% PD-L1 expr...
Clinicaltrials.gov 2 results
Oct 8th, 2015 - This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment at a dosage of 80 mg bid for 18 weeks (126 days) in patients with Polycythemia Vera (PV) who have abnormal baseline neut...
Apr 5th, 2011 - The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosp...
News 3 results
Jun 3rd, 2015 - The differential diagnosis of painful cutaneous ulcers in the setting of hematologic malignancy includes a variety of infectious and inflammatory etiologies such as ulcerative HSV, cytomegalovirus, Epstein-Barr virus, amoebic skin ulcerations, opp.
May 1st, 2014 - Conclusion This case describes a patient with two risk factors for CVT, a life-threatening condition. It should be considered in patients with ET and/or pregnant and postpartum patients presenting with headache or other neurological symptoms.
Rohtesh S. Mehta, MD, MPH, MS, David Cohen, MD
Sep 4th, 2013 - A 62-year-old white man with a past medical history of hypertension and essential thrombocytosis diagnosed 17 years ago presented at our institution. He was being treated with hydroxyurea, with which he required occasional blood transfusions and p.